Murraya koenigii Linn. Modulate diabetic neuropathy via attenuation of mechanical hyperalgesia and allodynia in STZ-induced diabetic rats

Introduction: The present research aims to examine the efficacy of Murraya koenigii (L.) extracts in the management of diabetic peripheral neuropathy (DPN). Methods: A dose of 65 mg/kg of streptozotocin (STZ) was administered intraperitoneally (i.p.) in fresh citrate buffer with a pH of 4.5 to induce diabetes 15 min after nicotinamide (230 mg/kg, ip) was administered and on 60th day development of DPN was evaluated by measuring behavioural parameters like tactile allodynia and hyperalgesia. In-vitro and in-vivo techniques were employed for estimation of oxidative stress. Results: Oral administration of extracts at various doses as well as standard drug was continued up to 90th day after 60th day of STZ-NAD administration. In diabetic animals, antioxidants like as SOD and GSH levels was reduced while the level of TBARS, nitrites, TNF-α, and AGE production were significantly increased. These extracts were discovered to positively impact fasting blood sugar levels, food intake, and body weight loss management. Furthermore, research demonstrated that the extracts had positive impact on pain perception as measured by thermal and mechanical hyperalgesia in experimental rats. Studies of these extracts, both in-vivo and in-vitro, indicated their potential to reduce oxidative stress as well as hyperglycemia, which are crucial in the progression of diabetes complications. Conclusion: It can be concluded that Murraya koenigii (L.) leaf extracts, ameliorates diabetes and diabetic peripheral neuropathy by regulating hyperglycemia and oxidative stress.